Pyridine and pyrazine derivative for the treatment of CF
US8247436B2 · kind B2 · utility
73Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2011 |
| Grant date | Aug 21, 2012 |
| Priority date | — |
| Expiry date | Mar 14, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.